JP Morgan Chase
DNLI icon

JP Morgan Chase’s Denali Therapeutics DNLI Stock Holding History

JP Morgan Chase’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,000
Closed -$408K – 7206
2025
Q1 		$408K Buy
+30,000
New +$575K ﹤0.01% 4893
2024
Q3 		– Sell
-30,000
Closed -$697K – 7463
2024
Q2 		$697K Buy
+30,000
New +$576K ﹤0.01% 4500

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's DNLI Position: Q2 2026 in Review

JP Morgan Chase reduced its Denali Therapeutics (DNLI) stake by 11% in Q2 2026, selling an estimated $760K and leaving 287,019 shares worth $7.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

JP Morgan Chase first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $27.7M in Q4 2020. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • JP Morgan Chase held 287,019 shares of Denali Therapeutics worth $7.59M as of Q2 2026.
  • JP Morgan Chase sold 36,970 Denali Therapeutics shares in Q2 2026, an estimated $760K.
  • Denali Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3060 holding.
  • JP Morgan Chase first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
  • JP Morgan Chase's Denali Therapeutics position peaked at $27.7M in Q4 2020.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.